PV Bulletin

Choline Salicylate PSUSA/00000732/202512 - Safety Update Assessment

New regulatory outcomes for choline salicylate established warnings regarding pregnancy and peptic ulcer history.

Primary source: View

PV Impact Brief

Urgency: HighConfidence: high

What changed

Choline salicylate products must now include warnings about not using them during the last trimester of pregnancy and advise caution during the first six months unless absolutely necessary. Additionally, warnings must be included for patients with a history of or current peptic ulcers.

Why it matters

These regulatory updates are crucial for compliance in pharmacovigilance and ensure that healthcare providers are aware of potential risks associated with choline salicylate, thereby protecting patients.

Action needed

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

Relevant for
Regulatory Intelligence Lead
Processes impacted
Signal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 28, 2026

Full briefing

Practical implication

Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

The EMA has issued a variation for choline salicylate's marketing authorization, including updated safety warnings. These changes are based on a periodic safety update assessment (PSUSA) and affect labeling requirements.

What changed: Choline salicylate products must now include warnings about not using them during the last trimester of pregnancy and advise caution during the first six months unless absolutely necessary. Additionally, warnings must be included for patients with a history of or current peptic ulcers.

Why it matters: These regulatory updates are crucial for compliance in pharmacovigilance and ensure that healthcare providers are aware of potential risks associated with choline salicylate, thereby protecting patients.

Practical implication: Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.

View original source

  • Source: EMA - What's new
  • Published at source: 2026-08-28T12:38:47.000Z
  • Discovered by monitor: 2026-08-29T05:25:08.258Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Safety Signals#Reporting Requirement#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward